These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

307 related items for PubMed ID: 11382717

  • 1. Monitoring platelet function in glycoprotein IIB/IIIA inhibitor therapy.
    Wu KK, Willerson JT.
    Circulation; 2001 May 29; 103(21):2528-30. PubMed ID: 11382717
    [No Abstract] [Full Text] [Related]

  • 2. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Bhatt DL, Topol EJ.
    JAMA; 2000 Sep 27; 284(12):1549-58. PubMed ID: 11000650
    [Abstract] [Full Text] [Related]

  • 3. Differences among the parenteral platelet glycoprotein IIb/IIIa inhibitors and implications for treatment.
    Tcheng JE.
    Am J Cardiol; 1999 May 06; 83(9A):7E-11E. PubMed ID: 10357575
    [No Abstract] [Full Text] [Related]

  • 4. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study.
    Steinhubl SR, Talley JD, Braden GA, Tcheng JE, Casterella PJ, Moliterno DJ, Navetta FI, Berger PB, Popma JJ, Dangas G, Gallo R, Sane DC, Saucedo JF, Jia G, Lincoff AM, Theroux P, Holmes DR, Teirstein PS, Kereiakes DJ.
    Circulation; 2001 May 29; 103(21):2572-8. PubMed ID: 11382726
    [Abstract] [Full Text] [Related]

  • 5. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
    Batchelor WB, Tolleson TR, Huang Y, Larsen RL, Mantell RM, Dillard P, Davidian M, Zhang D, Cantor WJ, Sketch MH, Ohman EM, Zidar JP, Gretler D, DiBattiste PM, Tcheng JE, Califf RM, Harrington RA.
    Circulation; 2002 Sep 17; 106(12):1470-6. PubMed ID: 12234950
    [Abstract] [Full Text] [Related]

  • 6. Emergency coronary artery bypass surgery in the era of glycoprotein IIb/IIIa receptor antagonist use.
    Pang JT, Fort S, Della Siega A, Cohen EA.
    J Card Surg; 2002 Sep 17; 17(5):425-31. PubMed ID: 12630543
    [Abstract] [Full Text] [Related]

  • 7. A risk stratification scheme for selection of a glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention based on clinical and angiographic criteria.
    Kini AS, Reich D, Mitre CA, Sharma SK.
    Am J Cardiol; 2001 Dec 01; 88(11):1287-90. PubMed ID: 11728356
    [No Abstract] [Full Text] [Related]

  • 8. Platelet aggregation inhibition with glycoprotein IIb--IIIa inhibitors.
    Proimos G.
    J Thromb Thrombolysis; 2001 Apr 01; 11(2):99-110. PubMed ID: 11406724
    [Abstract] [Full Text] [Related]

  • 9. Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective.
    Dyke CM.
    Am Heart J; 1999 Oct 01; 138(4 Pt 2):307-16. PubMed ID: 10502236
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials.
    Gurm HS, Tamhane U, Meier P, Grossman PM, Chetcuti S, Bates ER.
    Circ Cardiovasc Interv; 2009 Jun 01; 2(3):230-6. PubMed ID: 20031720
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [New thrombocyte aggregation inhibitor in therapy of unstable angina].
    Hamm C.
    Z Kardiol; 2000 Nov 01; 89(11):1053-6. PubMed ID: 11149273
    [Abstract] [Full Text] [Related]

  • 14. Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors: position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors.
    Aster RH, Curtis BR, Bougie DW, Dunkley S, Greinacher A, Warkentin TE, Chong BH, Scientific and Standardization Committee of The International Society On Thrombosis and Haemostasis.
    J Thromb Haemost; 2006 Mar 01; 4(3):678-9. PubMed ID: 16460451
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effects Of Glycoprotein IIb/IIIa Antagonists: Anti Platelet Aggregation And Beyond.
    Giordano A, Musumeci G, D'Angelillo A, Rossini R, Zoccai GB, Messina S, Coscioni E, Romano S, Romano MF.
    Curr Drug Metab; 2016 Mar 01; 17(2):194-203. PubMed ID: 26652157
    [Abstract] [Full Text] [Related]

  • 17. Platelet glycoprotein IIb/IIIa receptor blockers: An appropriate-use model for expediting care in acute coronary syndromes.
    Kereiakes DJ, McDonald M, Broderick T, Roth EM, Whang DD, Martin LH, Howard WL, Schneider J, Shimshak T, Abbottsmith CW.
    Am Heart J; 2000 Feb 01; 139(2 Pt 2):S53-60. PubMed ID: 10650317
    [No Abstract] [Full Text] [Related]

  • 18. Therapeutics of platelet glycoprotein IIb/IIIa receptor antagonism.
    Gowda RM, Khan IA, Vasavada BC, Sacchi TJ.
    Am J Ther; 2004 Feb 01; 11(4):302-7. PubMed ID: 15266223
    [Abstract] [Full Text] [Related]

  • 19. Meta-analysis of effectiveness and safety of abciximab versus eptifibatide or tirofiban in percutaneous coronary intervention.
    Brown DL, Fann CS, Chang CJ.
    Am J Cardiol; 2001 Mar 01; 87(5):537-41. PubMed ID: 11230835
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.